Insider Buying: Carmell Co. (NASDAQ:CTCX) CEO Acquires $24,998.40 in Stock

Carmell Co. (NASDAQ:CTCX) CEO Rajiv Shukla acquired 8,680 shares of the firm’s stock in a transaction on Thursday, April 4th. The stock was bought at an average price of $2.88 per share, with a total value of $24,998.40. Following the purchase, the chief executive officer now directly owns 57,206 shares of the company’s stock, valued at $164,753.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Rajiv Shukla also recently made the following trade(s):

• On Wednesday, May 22nd, Rajiv Shukla acquired 4,051 shares of Carmell stock. The stock was bought at an average price of $2.41 per share, with a total value of $9,762.91.
• On Monday, May 20th, Rajiv Shukla bought 1,172 shares of Carmell stock. The shares were acquired at an average price of $2.22 per share, with a total value of $2,601.84.

Carmell Trading Up 2.4 %

Carmell stock traded up $0.06 during mid-day trading on Friday, reaching $2.57. The company had a trading volume of 85,562 shares, compared to its average volume of 12,538. Carmell Co. has a 1 year low of $1.70 and a 1 year high of $13.31. The stock’s 50-day simple moving average is $2.36 and its 200-day simple moving average is $2.91.

Institutional Trading of Carmell

Hedge funds have recently bought and sold shares of the company. Hubbell Strickland Wealth Management LLC acquired a new position in shares of Carmell in the 1st quarter valued at $32,000. Cookson Peirce & Co. Inc. acquired a new position in shares of Carmell in the 3rd quarter valued at $54,000. Linden Advisors LP acquired a new position in shares of Carmell in the 3rd quarter valued at $270,000. Finally, Meteora Capital LLC acquired a new position in shares of Carmell in the 3rd quarter valued at $6,416,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Carmell Company Profile

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.